CAPTYN, a Blood-Based Machine-Learning Model Predicting Clinical Benefit of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: Validation in the IMbrave150 Trial.
Journal:
Cancer communications (London, England)
Published Date:
Oct 19, 2026
Abstract
No abstract available for this article.
Authors
Keywords
No keywords available for this article.
